Diagnosis

Cushing syndrome

The clinical state resulting from excess tissue exposure to cortisol and/or other glucocorticoids.

Also known as: Hypercortisolemia, Hypercortisolism

Etiology

Cause [eo9][s87]

  1. Exogenic: Iatrogenic Cushing syndrome (the most common cause) [eo9]

  2. Endogenic:

    • ACTH dependent:

      • Pituitary tumor secreting ACTH (Cushings disease): common endogenic cause

      • Ectopic ACTH secretion by tumor (small cell lung cancer)

    • ACTH independent:

      • Functional adrenal adenoma secretes cortisol

      • Functional adrenal carcinoma

      • Adrenal hyperplasia

  3. Pseudo-Cushing syndrome: Other causes for elevated plasma cortisol:

    • Psychiatry: Chronic stress, depression, anorexia nervosa, OCD, panic disorder

    • Excessive exercise

    • Drugs: Chronic alcoholism, alcohol and nicotine withdrawal

    • Metabolic: Diabetes mellitus, central obesity, hyperthyroidism, premenstrual tension syndrome, pregnancy

Pathophysiology [eo9]

  1. The hypothalamic-pituitary-adrenal axis:

    1. Hypothalamus: Corticotrophin Releasing Hormone (CRH

    2. Adenohypophysis (pituitary gland): AdrenoCorTicotropic Hormone (ACTH)

    3. Adrenal cortex:

      • Zona glomerulosa: aldosterone

      • Zona fasciculata: Baseline cortisol production + Secretory responses to stimuli

      • Zona reticularis: adrenal androgens

      • Cortisol inhibit pituitary ACTH and hypothalamic CRH (negative feedback)

  2. Derangement of the hypothalamic-pituitary-adrenal axis:

    • Fatigue, muscle weakness, osteoporosis, hypertension, hyperglycemia/diabetes, facial plethora, proximal myopathy, pigmented palpable striae, cutaneous bruising, central weight gain, headaches, dizziness, visual blurring, polyuria, polydipsia, polyphagia, anorexia, oligomenorrhea, amenorrhea, infertility, reduced libido, erectile dysfunction, arrested growth, sleep deprivation, mood decline, depression, psychotic episodes, hirsutism, acne, moon face, facial flushing, malar telangiectasia, enlarged dorsocervical pad (buffalo hump), supraclavicular fat pad, scalp hair loss, hyperpigmentation

Complications [eo9]

Epidemiology

Incidence per 100.000

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Acne, Amenorrhea, Buffalo hump, Decreased libido, Depression, Hirsutism, Hyperpigmentation, Hypertension, Impaired memory, Moon face, Muscle atrophy, Muscle weakness, Obesity, Stria, Weight gain

Clinical findings

Elevated Cortisol, Elevated Hematocrit, Elevated Hemoglobin, Hyperglycemia, Osteoporosis, Polycythemia

Anamneses

Diabetes mellitus

Localized findings

Rash
Radiates
CaputCollumThoraxArmBackLower body
Distribution
GeneralizedLocalizedMultipleSymmetric
Lesion type
ComedoneNodulePapuleSeborrhea
Color
BlackRedWhite
Associated symptom
BleedingDischargeItchSwelling

Approach

Treatment

  1. Medical treatment: [zft]

    • Iatrogenic: gradual withdrawal of the causative drug

    • Inhibitors of ACTH: Pasireotide (somatostatin receptor ligand)

    • Adrenal inhibition: Ketoconazole, Metyrapone, Mitotane and Etomidate

    • Glucocorticoid receptor blockade: Mifepristone

    • Treatment of comorbidities (hypertension, diabetes, obesity, dyslipidemia)

  2. Surgical resection of the causative tumor [zft]

    • Pituitary surgery

    • Adrenalectomy (bilateral if pituitary therapy fail or ectopic ACTH-producing tumors are difficult to locate/resect)

    • Ectopic ACTH --> resection of metastatic adrenal carcinoma

  3. Pituitary radiation therapy

Differential diagnoses

Alcoholism, Cancer origo incerta, Cushings disease, Depression, Lipodystrophy Syndromes, Obesity, Primary Generalized Glucocorticoid Resistance Syndrome


References

[1] Uwaifo GI, Hura DE. Hypercortisolism. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551526/

[2] Lindholm J, Juul S, Jørgensen JO, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117-123.

[3] https://emedicine.medscape.com/article/2233083

[4] Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH. Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States. Pituitary. 2015 Jun;18(3):283-9.

[5] Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol (Oxf). 2011;75(4):436-442.

[6] Wengander S, Trimpou P, Papakokkinou E, Ragnarsson O. The incidence of endogenous Cushing’s syndrome in the modern era. Clin Endocrinol (Oxf). 2019;91(2):263-270.

[7] Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101521.

[8] Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001 Jan;86(1):117-23.

Scroll to top